Please login to the form below

Not currently logged in
Email:
Password:

Amryt Pharma appoints new regulatory affairs head

Derval O’Carroll joins the rare disease-focused biopharma from Retrophin

Rare and orphan disease-focused biopharmaceutical group Amryt Pharma has appointed a new head of regulatory affairs in the form of Derval O’Carroll.

O’Carroll has over 25 years’ experience in the pharmaceutical industry and regulatory affairs business. Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

Her previous roles have seen her provide regulatory, strategic and operational input to product teams and managing development-stage and commercial products.

Prior to her time at Retrophin, O’Carroll spent eleven years as a managing consultant at Real Regulatory, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance.

Her new role will see her take responsibility for engagement with regulatory agencies and she will examine opportunities to pursue new orphan indications for Amryt’s Epidermolysis bullosa candidate.

Dr Joe Wiley, chief executive officer or Amryt Pharma, said: “We are delighted to further strengthen our senior management team with the appointment of Derval as head of regulatory affairs.

“Her expertise will be particularly valuable as we plan for completion of our ongoing AP101 phase III trial in EB.”

1st February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...